赖氨加压素结构式
|
常用名 | 赖氨加压素 | 英文名 | [Lys8]-Vasopressin TFA |
---|---|---|---|---|
CAS号 | 50-57-7 | 分子量 | 1056.218 | |
密度 | 1.3±0.1 g/cm3 | 沸点 | 1610.4±65.0 °C at 760 mmHg | |
分子式 | C46H65N13O12S2 | 熔点 | N/A | |
MSDS | 中文版 美版 | 闪点 | 927.7±34.3 °C | |
符号 |
GHS07 |
信号词 | Warning |
赖氨加压素用途Lysipressin 是一个从猪身上发现的抗利尿激素, 能够诱发兔膀胱平滑肌的收缩,激活腺苷酸环化酶。 |
中文名 | 赖氨加压素 |
---|---|
英文名 | Lypressin |
中文别名 | 醋酸赖氨酸加压素 | 醋酸赖加压素 | 醋酸赖氨酸加压素 LYSIPRESSINACETATE | 赖氨酸加压素(LYSPRESSIN) | 赖加压素 |
英文别名 | 更多 |
描述 | Lysipressin 是一个从猪身上发现的抗利尿激素, 能够诱发兔膀胱平滑肌的收缩,激活腺苷酸环化酶。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 1610.4±65.0 °C at 760 mmHg |
分子式 | C46H65N13O12S2 |
分子量 | 1056.218 |
闪点 | 927.7±34.3 °C |
精确质量 | 1055.431763 |
PSA | 476.15000 |
LogP | -5.74 |
外观性状 | 白色粉末 |
蒸汽压 | 0.0±0.3 mmHg at 25°C |
折射率 | 1.581 |
储存条件 | −20°C |
稳定性 | 本品是哺乳动物如猪等脑下垂体后叶分泌激素之一,它由下丘脑的视丘核产生再经轴突运输到垂体后叶,然后再由后叶分泌出来。是含有九个氨基酸残基的活性肽之一,因其中两个半胱氨酸由二硫键相连而作为一个胱氨酸(Cys-Cys)计时又称为八肽。除从垂体后叶提取外,也可人工合成、它具有抗利尿和升血压作用,为此称它为抗利尿激素(antidiuretic hormone)或加压素(vasopressin)。 |
赖氨加压素上游产品 0 | |
---|---|
赖氨加压素下游产品 2 | |
Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.
PLoS ONE 8(1) , e52683, (2013) Only a limited proportion of patients needing pharmacological control of portal hypertension are hemodynamic responders to propranolol. Here we analyzed the effects of zolmitriptan on portal pressure ... |
|
Effects of terlipressin on microcirculation of small bowel mesentery in rats with endotoxic shock
J. Surg. Res. 188(2) , 503-9, (2014) Background Septic shock is still related to unacceptably high morbidity and mortality. Microcirculatory alteration has been demonstrated to be one important reason associated with this evolution. Vaso... |
|
Terlipressin resolves ascites of cirrhotic rats through downregulation of aquaporin 2.
J. Int. Med. Res. 40(5) , 1735-44, (2012) To investigate the presence of aquaporin (AQP) 1 and AQP2 in kidneys of cirrhotic rats with ascites, and to determine the effect of terlipressin on AQP1 and AQP2 levels and its therapeutic efficacy in... |
EINECS 200-050-5 |
syntopressin |
postacton |
Lysipressin Acetate |
CYFQNCPKG-NH2 |
LVP |
[Lys8]-vasopressin |
LYSPRESSIN |
lypressin |
8-lysine-vasopressin |
lysinepitressin |
diapid |
lysine-vasopressin |
Glycinamide, 1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentaazacycloeicos-4-yl]carbonyl]-L-prolyl-L-lysyl- |
L-Cysteinyl-L-tyrosyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-lysylglycinamide Cyclic (1®6)-Disulfide |
(8-Lysine)vasopressin |
1-{[(4R,7S,10S,13S,16S,19R)-19-Amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-L-lysylglycinamide |
Lysipressin |
Lysine Vasopressin |
Cys-Pro-Arg-Gly-NH2 |
c[Cys-Tyr-Phe-Gln-Asn-Cys]-Pro-Lys-Gly-NH2 |
CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2(DISULFIDE BRIDGE:CYS1-CYS6) |
Lypressin Acetate |